Gland Pharma Limited
Symbol: GLAND.NS
NSE
1708.85
INRMarkedspris i dag
42.9265
P/E-forhold
1.6233
PEG Ratio
281.47B
MRK Cap
- 0.00%
DIV Udbytte
Gland Pharma Limited (GLAND-NS) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 119605.7 | 38362 | 32427.2 | 24465 | |||||||
balance-sheet.row.short-term-investments | 154862.64 | 19273 | 29268.9 | 19546.8 | |||||||
balance-sheet.row.net-receivables | 22690.46 | 8715.3 | 12514.7 | 12726.8 | |||||||
balance-sheet.row.inventory | 40296.48 | 19453 | 11856.7 | 12751.7 | |||||||
balance-sheet.row.other-current-assets | 5282.69 | 2477.8 | 1722.3 | 1292.9 | |||||||
balance-sheet.row.total-current-assets | 187875.33 | 69008.1 | 58520.8 | 51236.4 | |||||||
balance-sheet.row.property-plant-equipment-net | 51493.3 | 17361 | 17269 | 13244.4 | |||||||
balance-sheet.row.goodwill | 4555.95 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 1656.81 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 6212.76 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.long-term-investments | -16835.11 | -733.7 | 2000 | -19477.3 | |||||||
balance-sheet.row.tax-assets | 1402.64 | 958.9 | -415.1 | 0 | |||||||
balance-sheet.row.other-non-current-assets | -39445.19 | 1064.4 | 836.1 | 19957.3 | |||||||
balance-sheet.row.total-non-current-assets | 2828.4 | 18767.3 | 19815.4 | 13724.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 190703.73 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.account-payables | 15655.98 | 5873.5 | 4628.5 | 4007.3 | |||||||
balance-sheet.row.short-term-debt | 2102.99 | 7.1 | 2.6 | 3 | |||||||
balance-sheet.row.tax-payables | 624.79 | 9.8 | 179.8 | 286.9 | |||||||
balance-sheet.row.long-term-debt-total | 1511.84 | 37.4 | 44.8 | 47 | |||||||
Deferred Revenue Non Current | 1298.89 | 49.9 | 55.5 | 56.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 2180.49 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 3290.63 | 924.7 | 552.6 | 63.3 | |||||||
balance-sheet.row.total-non-current-liabilities | 5396.07 | 896.8 | 939.8 | 803.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 449.53 | 6.3 | 8.1 | 9.3 | |||||||
balance-sheet.row.total-liab | 28049.42 | 8188.1 | 6760 | 5928.4 | |||||||
balance-sheet.row.preferred-stock | 15.59 | 15.6 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 329.4 | 164.7 | 164.3 | 163.6 | |||||||
balance-sheet.row.retained-earnings | 60153.88 | 60153.9 | 52343.4 | 40226.8 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 245541.11 | -15.6 | 114.5 | 240.9 | |||||||
balance-sheet.row.other-total-stockholders-equity | 19268.64 | 19268.6 | 18953.9 | 18401.1 | |||||||
balance-sheet.row.total-stockholders-equity | 325308.62 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 353358.04 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 325308.62 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 353358.04 | - | - | - | |||||||
Total Investments | 138027.53 | 18539.3 | 2000 | 69.5 | |||||||
balance-sheet.row.total-debt | 3614.83 | 44.5 | 47.4 | 50 | |||||||
balance-sheet.row.net-debt | 38871.77 | -19044.4 | -3110.8 | -4868.3 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 6587.23 | 10545.8 | 16185.5 | 13348.1 | |||||||
cash-flows.row.depreciation-and-amortization | 2894.99 | 1467.4 | 1103 | 987.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -4143.8 | -3254 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 46.2 | 155.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -4179.4 | -3930.8 | -4357.6 | |||||||
cash-flows.row.account-receivables | 0 | 1440 | -4195.7 | -602 | |||||||
cash-flows.row.inventory | 0 | -7596.3 | 895 | -5188.9 | |||||||
cash-flows.row.account-payables | 0 | 1209.8 | 658.5 | 1428.2 | |||||||
cash-flows.row.other-working-capital | 0 | 767.2 | -1288.6 | 5.1 | |||||||
cash-flows.row.other-non-cash-items | -6587.23 | -4194.1 | -1352.4 | -830.4 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 5789.98 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.acquisitions-net | 0 | -12705.6 | 6117.2 | 4.3 | |||||||
cash-flows.row.purchases-of-investments | 0 | -4699.8 | -16818.1 | -13575.9 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 17405.4 | 10700.9 | -4.3 | |||||||
cash-flows.row.other-investing-activites | 0 | 14313.1 | -4805 | 623.7 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 12081.9 | -10026.2 | -15240 | |||||||
cash-flows.row.debt-repayment | 0 | -1.1 | -1.4 | -8.9 | |||||||
cash-flows.row.common-stock-issued | 0 | 215 | 385.5 | 12418.1 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -64.7 | -35.2 | -24.6 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 149.2 | 349 | 12384.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 30 | 33.1 | 35.8 | |||||||
cash-flows.row.net-change-in-cash | 5789.98 | 15900.8 | -1736.4 | 3229.7 | |||||||
cash-flows.row.cash-at-end-of-period | 51207.44 | 19089 | 3188.2 | 4924.6 | |||||||
cash-flows.row.cash-at-beginning-of-period | 45417.46 | 3188.2 | 4924.6 | 1695 | |||||||
cash-flows.row.operating-cash-flow | 5789.98 | 3639.7 | 7907.7 | 6049.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.free-cash-flow | 5789.98 | 1408.5 | 2686.5 | 3761.5 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 49122.83 | 36246 | 43841.4 | 34236.4 | |||||||
income-statement-row.row.cost-of-revenue | 19385.47 | 16854.3 | 21092.2 | 14918.7 | |||||||
income-statement-row.row.gross-profit | 29737.36 | 19391.7 | 22749.3 | 19317.6 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 2016 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 1670.27 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.operating-expenses | 21203.94 | 10611.5 | 8745.5 | 7280.4 | |||||||
income-statement-row.row.cost-and-expenses | 40589.41 | 27465.7 | 29837.7 | 22199.2 | |||||||
income-statement-row.row.interest-income | 1783.74 | 1794.2 | 1386.5 | 859.5 | |||||||
income-statement-row.row.interest-expense | 184.45 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 190.97 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 1670.27 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.total-operating-expenses | 190.97 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.interest-expense | 184.45 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.depreciation-and-amortization | 2894.99 | 1467.4 | 1103 | 987.8 | |||||||
income-statement-row.row.ebitda-caps | 12534.07 | - | - | - | |||||||
income-statement-row.row.operating-income | 9263.66 | 8844.4 | 14000.3 | 12034.5 | |||||||
income-statement-row.row.income-before-tax | 9454.63 | 10545.8 | 16185.5 | 13348.1 | |||||||
income-statement-row.row.income-tax-expense | 2867.4 | 2735.4 | 4068.9 | 3378.5 | |||||||
income-statement-row.row.net-income | 6587.23 | 7810.4 | 12116.6 | 9969.6 |
Ofte stillede spørgsmål
Hvad er Gland Pharma Limited (GLAND.NS) samlede aktiver?
Gland Pharma Limited (GLAND.NS) samlede aktiver er 87775350000.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er 29185790000.000.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.605.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er 35.155.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er 0.134.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er 0.189.
Hvad er Gland Pharma Limited (GLAND.NS) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er 7810430000.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 44530000.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 10611470000.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er -21447340000.000.